Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 17Etoposide 10fludarabine 9Whole-Body Irradiation 9Brentuximab Vedotin 9Melphalan 8fludarabine phosphate 7Vincristine 7Mycophenolic Acid 7Gemcitabine 7Doxorubicin 7Prednisone 6Granulocyte Colony-Stimulating Factor 6Busulfan 6Vorinostat 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Filgrastim 5Cytarabine 5Bortezomib 5romidepsin 4pembrolizumab 4duvelisib 4Tacrolimus 4Stem Cell Transplantation 4Carmustine 4etoposide phosphate 3Sirolimus 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell × Pyridoxine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡